Tuesday, 6 October 2026European Markets

ADYEN Stock Went Down By Over 18% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ADYEN (AEX-Index: ADYEN.AS) fell by a staggering 18.06% in 5 sessions from 1617.53 € to 1,325.40 € at 01:08 EST on Monday, following the last session's upward trend. AEX-Index is falling 0.64% to 752.22 €, following the last session's upward trend.

About ADYEN

Adyen N.V. operates a payments platform in Europe, the Middle East, Africa, North America, the Asia Pacific, Latin America. The company's platform integrates payments stack that include gateway, risk management, processing, issuing, acquiring, and settlement services. It offers a back-end infrastructure for authorizing payments across merchants' sales channels, as well as online, mobile, in-store, and APIs; and data insights. The company's platform services a range of merchants across various verticals, connecting them directly to Visa, Mastercard, and other payment methods. Adyen N.V. was incorporated in 2006 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ADYEN has a trailing twelve months EPS of 18.61 €.

PE Ratio

ADYEN has a trailing twelve months price to earnings ratio of 71.22. Meaning, the purchaser of the share is investing 71.22 € for every euro of annual earnings.

Volatility

ADYEN's last week, last month's, and last quarter's current intraday variation average was a negative 8.41%, a negative 0.01%, and a positive 2.31%.

ADYEN's highest amplitude of average volatility was 8.41% (last week), 3.01% (last month), and 2.31% (last quarter).

More news about ADYEN (ADYEN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com